Back to results
US 10,500,183 B2Granted
Acetylcholinesterase inhibitors for treatment of dermatological conditions
AssigneeAttillaps Holdings
InventorFrank Anthony Spallitta
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAttillaps Holdings
InventorFrank Anthony Spallitta
Estimating the term…
Embodiments of the invention involve treating skin afflictions by the topical or oral use of acetylcholinesterase inhibitor. By effectively reducing or eliminating the population of Demodex mites in affected skin areas and areas where Demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the skin afflictions than any previously described method. Embodiments of the invention are useful for treating skin afflictions including common acne, seborrheic dermatitis, perioral dermatitis, an acneform rash, transient acantholytic dermatosis, acne necrotica milliaris, psoriasis, steroid induced dermatitis, primary irritation dermatitis and rosacea.
A method of treating a skin affliction associated with Demodex brevis and/or Demodex folliculorum mites comprising a step of topically-applying to an individual having the skin affliction an acetylcholinesterase inhibitor selected from the group consisting of physostigmine, demecarium, donepezil, tacrine, echothiophate, diisopropyl fluorophosphate, lactucopicrin, boswellia, celastrus paniculatus, coumarins, galantamine, and huperzine A, or a prodrug or pharmaceutically acceptable salt thereof, in a dosage effective to inactivate Demodex brevis and/or Demodex folliculorum mites in hair follicles and/or skin of the individual, resulting in amelioration or cessation of the manifestations of allergic and/or vasomotor responses to the mites that cause symptoms and signs of the skin affliction in the individual.
A method of treating a skin affliction associated with Demodex brevis and/or Demodex folliculorum mites comprising a step of topically-applying to an individual having the skin affliction an active ingredient comprising an acetylcholinesterase inhibitor selected from the group consisting of physostigmine, demecarium, donepezil, tacrine, echothiophate, diisopropyl fluorophosphates, lactucopicrin, boswellia, celastrus paniculatus, coumarins, galantamine, and huperzine A, or a prodrug or pharmaceutically acceptable salt thereof, in a dosage sufficient to inactivate Demodex brevis and/or Demodex folliculorum mites in hair follicles and/or skin of the individual, resulting in amelioration or cessation of the manifestations of allergic and/or vasomotor responses to the mites that cause symptoms and signs of the skin affliction in the individual, wherein the topically-applied active ingredient is applied to skin areas affected by the skin affliction and to skin areas not affected by the skin affliction.
Dependencies are inferred from the claim text.